High Response Rates in Psoriasis With Oral IL-23 Inhibitor
An oral interleukin (IL)-23 inhibitor for psoriasis produced 16-week response rates as high as 79% in moderate-to-severe plaque psoriasis, a prospective phase II trial showed. The drug (JNJ-77242113) achieved response rates of 37% to 79% across five dose levels. In contrast, patients treated with placebo had a 9% response rate at 16 weeks. The most […]